Decision on IPR: Nov 20, 2018
|
AIA Review
|
Filing Date
|
Institution Date
|
Petitioner
|
US Patent
|
Respondent
|
Status
|
|
IPR2017-02019
|
08/29/2017
|
03/12/2018
|
Pfizer, Inc.
|
6,339,142
|
Genentech, Inc.
|
Terminated
|
|
IPR2017-02020
|
08/29/2017
|
03/12/2018
|
Pfizer, Inc.
|
9,249,218
|
Genentech, Inc.
|
Terminated
|
On US’142 & US’218 patents, Pfizer previously filed IPRs (IPR2018-00330 & IPR2018-00331) on 12/18/2017 which were denied by PTAB.
US 6,339,142 (Genentech, Inc.; Exp: May 03, 2019):
1. A composition comprising a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%.
US 9,249,218 (Genentech, Inc.; Exp: May 03, 2019*TD):
1. A therapeutic composition comprising a mixture of anti-HER2 antibody and one or more acidic variants thereof, wherein the amount of the acidic variant(s) is less than about 25%, and wherein the acidic variant(s) are predominantly deamidated variants wherein one or more asparagine residues of the anti-HER2 antibody have been deamidated, and wherein the anti-HER2 antibody is humMAb4D5-8, and wherein the deamidated variants have Asn30 in CDR1 of either or both V.sub.L regions of humMAb4D5-8 converted to aspartate, and a pharmaceutically acceptable carrier.
Leave a Reply